# Comparison of Atezolizumab/Bevacizumab Versus Durvalumab/Tremelimumab (STRIDE) Protocols in Locally Advanced or Metastatic Hepatocellular Carcinoma Among Patients in Sohag

> **NCT07669597** · — · ACTIVE_NOT_RECRUITING · sponsor: **Sohag Oncology Center** · enrollment: 50 (estimated)

## Conditions studied

- Locally Advanced or Metastatic Hepatoceullar Carcinoma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07669597
- **Lead sponsor:** Sohag Oncology Center
- **Sponsor class:** OTHER_GOV
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2026-03-01
- **Primary completion:** 2027-03-01
- **Final completion:** 2027-06-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07669597

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07669597, "Comparison of Atezolizumab/Bevacizumab Versus Durvalumab/Tremelimumab (STRIDE) Protocols in Locally Advanced or Metastatic Hepatocellular Carcinoma Among Patients in Sohag". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07669597. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*